Soft tissue and visceral sarcomas: ESMO clinical practice guidelines for diagnosis, treatment andfollow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CEDIRANIB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; GESTAGEN; GONADORELIN; IFOSFAMIDE; IMATINIB; INTERFERON; METHOTREXATE; NAVELBINE; PAZOPANIB; RIDAFOROLIMUS; SUNITINIB; TAXANE DERIVATIVE; TRABECTEDIN; VINBLASTINE;

ABDOMINAL HYSTERECTOMY; ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; ANGIOSARCOMA; ARTICLE; BREAST SARCOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; DERMATOFIBROSARCOMA PROTUBERANS; DESMOID TUMOR; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ENDOMETRIUM SARCOMA; FIBROMATOSIS; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; LEIOMYOSARCOMA; LIPOSARCOMA; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROPERITONEAL SARCOMA; RISK ASSESSMENT; SALPINGOOOPHORECTOMY; SOFT TISSUE SARCOMA; TUMOR BIOPSY; UTERUS SARCOMA;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROPERITONEAL NEOPLASMS; RISK ASSESSMENT; SARCOMA; UTERINE NEOPLASMS;

EID: 84866603440     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds253     Document Type: Article

References (30)

1. Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 2011; 47: 2493-2511.
2. Trojani M, Contesso G, Coindre JM et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer 1984; 33: 37-42.
3. Soft tissue sarcoma. In American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6th edition. New York: Springer; 2002. p. 193-197.
4. Eggermont AMM. Isolated limb perfusion in the management of locally advanced extremity soft tissue sarcoma. Surg Oncol Clin N Am 2003; 12: 469-483.
5. Pervaiz N, Colterjohn N, Farrokhyar F et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008; 113: 573-581.
6. Gronchi A, Frustaci S, Mercuri M et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012; 30(8): 850-856.
7. Blackmon SH, Shah N, Roth JA et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 2009; 88: 877-884.
8. Antman K, Crowley J, Balcerzak SP et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993; 11: 1276-1285.
9. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008; 26: 5269-5274.
10. Rutkowski P, Van Glabbeke M, Rankin CJ. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010; 28(10):1772-1779.
11. Le Cesne A, Antoine E, Spielmann M et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. J Clin Oncol 1995; 13: 1600-1608.
12. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27: 4188-4196.
13. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007; 8: 595-602.
14. Maki RG, Wathen JK, Patel SR et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007; 25: 2755-2763.
15. García-Del-Muro X, López-Pousa A, Maurel J et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. J Clin Oncol 2011; 29(18): 2528-2533.
16. van der Graaf WT, Blay JY, Chawla SP et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379(9829): 1879-1886.
17. Chawla SP, Staddon AP, Baker LH et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30(1): 78-84.
18. Wagner AJ, Malinowska-Kolodziej I, Morgan JA et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010; 28 (5): 835-840.
19. Butrynski JE, D'Adamo DR, Hornick JL et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010; 363(18): 1727-1733.
20. Stacchiotti S, Tamborini E, Marrari A. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res 2009; 15(3): 1096-1104.
21. Kummar S, Strassberger A, Monks A et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). J Clin Oncol 2011; 29 (suppl; abstr 10001).
22. Bonvalot S, Rivoire M, Castaing M et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol 2009; 27: 31-37.
23. Bonvalot S, Raut CP, Pollock RE et al. Technical Considerations in Surgery for Retroperitoneal Sarcomas: Position Paper from E-Surge, a Master Class in Sarcoma Surgery, and EORTC-STBSG. Ann Surg Oncol 2012. [Epub 2012 Apr 3]
24. Amant F, Coosemans A, Debiec-Rychter M et al. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10: 1188-1198.
25. Reed NS, Mangioni C, Malmström H et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818.
26. Hensley ML, Ishill N, Soslow R et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009; 112(3): 563-567.
27. Fiore M, Rimareix F, Mariani L et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol 2009; 16: 2587-2593.
28. Janinis J, Patriki M, Vini L et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14: 181-190.
29. Gounder MM, Lefkowitz RA, Keohan ML et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011; 17(12): 4082-4090 [Epub 2011 Mar 29].
30. Edge SB, Byrd DR, Compton CC et al. (eds). AJCC Cancer Staging Manual. 7thed. New York: Springer 2010.